Cardiology Xagena
Data from the interim analysis of the on-going PATENT-2 trial with Riociguat ( Adempas ), the open-label long-term extension of the pivotal Phase III study PATENT-1, were presented at the American Tho ...
Deficient nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate signaling results from endothelial dysfunction and may underlie impaired cardiac relaxation in patients with heart failu ...